US approval of Brintellix first for Lundbeck/Takeda alliance
This article was originally published in Scrip
The US FDA has granted the first approval worldwide to Lundbeck's Brintellix (vortioxetine) as a treatment for adults with major depressive disorder, paving the way for the multi-modal therapy to become the first commercial product under the Danish firm's strategic alliance with Takeda.
You may also be interested in...
The alliance between China’s largest insurance group and Shionogi takes concrete shape as investment plans and new Asia companies move ahead, marking a major technology and geographic pivot for the Japanese pharma firm.
More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.